Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.N Engl J Med. 1990; 322: 1617-1621
- American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.Blood Adv. 2020; 4: 327-355
- Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.JAMA. 2014; 312: 1033-1048
- Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion.Br J Haematol. 2017; 176: 192-209
- Red blood cells: exchange, transfuse, or deplete.Transfus Med Hemother. 2019; 46: 407-416
- Evaluation and treatment of transfusional iron overload in children.Pediatr Clin North Am. 2013; 60: 1393-1406
- Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB.Transfusion. 2018; 58: 1965-1972
- Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for apheresis: the Eighth special Issue.J Clin Apher. 2019; 34: 171-354
- Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease.Pediatr Blood Cancer. 2011; 57: 294-296
- How I treat and manage strokes in sickle cell disease.Blood. 2015; 125: 3401-3410
- Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.N Engl J Med. 1998; 339: 5-11
- Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results.Blood. 2006; 108: 847-852
- Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.N Engl J Med. 2005; 353: 2769-2778
- Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.Lancet. 2016; 387: 661-670
- The natural history of stroke in sickle cell disease.Am J Med. 1978; 65: 461-471
- Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.J Pediatr. 2002; 140: 348-354
- Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease.Blood. 2011; 117: 772-779
- Stroke with transfusions changing to hydroxyurea (SWiTCH).Blood. 2012; 119: 3925-3932
- Silent infarcts in young children with sickle cell disease.Br J Haematol. 2009; 146: 300-305
- Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease.Blood. 2002; 99: 3014-3018
- Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease.Neurology. 2001; 56: 1109-1111
- Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease.J Pediatr. 2001; 139: 385-390
- Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.N Engl J Med. 2014; 371: 699-710
- Mortality in sickle cell disease. Life expectancy and risk factors for early death.N Engl J Med. 1994; 330: 1639-1644
- Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.N Engl J Med. 2000; 342: 1855-1865
- Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults.Transfusion. 2009; 49: 863-868
- Comparison of automated red cell exchange transfusion and simple transfusion for the treatment of children with sickle cell disease acute chest syndrome.Pediatr Blood Cancer. 2013; 60: 1952-1956
- Effect of transfusion in acute chest syndrome of sickle cell disease.J Pediatr. 1995; 127: 901-904
- The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.Blood. 1994; 84: 643-649
- Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome.J Pediatr Hematol Oncol. 2005; 27: 158-161
- The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.Lancet. 2013; 381: 930-938
- A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group.N Engl J Med. 1995; 333: 206-213
- Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series.Transfusion. 2016; 56: 107-114
- Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival.Transfusion. 2015; 55: 1378-1387
- How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.Blood. 2018; 131: 2773-2781
- Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.Transfusion. 2019; 59: 2282-2291
- Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects.Br J Haematol. 2017; 176: 179-191
- Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.Br J Haematol. 2018; 181: 672-681
- Challenges of alloimmunization in patients with haemoglobinopathies.Br J Haematol. 2012; 159: 394-404
- High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.Blood. 2013; 122: 1062-1071
- Allosensitization in patients receiving multiple blood transfusions.Ann N Y Acad Sci. 2005; 1054: 495-499
- Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.Transfusion. 2001; 41: 1086-1092
- Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.Br J Haematol. 2015; 168: 291-300
- Mechanisms of alloimmunization in sickle cell disease.Curr Opin Hematol. 2019; 26: 434-441
- Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease.Transfusion. 2015; 55: 1388-1393
- Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME).Transfusion. 2011; 51: 1732-1739
- Management of patients with sickle cell disease using transfusion therapy: guidelines and complications.Hematol Oncol Clin North Am. 2016; 30: 591-608
- Impact of red blood cell antigen matching on alloimmunization and transfusion complications in patients with sickle cell disease: a systematic review.Transfus Med Rev. 2019; 33: 12-23
- Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals.Nat Genet. 1995; 10: 224-228
- Systematic RH genotyping and variant identification in French donors of African origin.Blood Transfus. 2014; 12: s264-s272
- Clinically relevant RHD-CE genotypes in patients with sickle cell disease and in African Brazilian donors.Blood Transfus. 2016; 14: 449-454
- The Rhesus site.Transfus Med Hemother. 2014; 41: 357-363
- Allelic genes of blood group antigens: a source of human mutations and cSNPs documented in the Blood Group Antigen Gene Mutation Database.Hum Mutat. 2004; 23: 8-16
- RH genotype matching for transfusion support in sickle cell disease.Blood. 2018; 132: 1198-1207
- Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.Hematol Oncol Clin North Am. 2014; 28 (vi): 703-727
- Cardiac iron overload in sickle-cell disease.Am J Hematol. 2014; 89: 678-683
- Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.PLoS One. 2017; 12: e0172147
- Chronically transfused pediatric sickle cell patients are protected from cardiac iron overload.Pediatr Hematol Oncol. 2012; 29: 254-260
- Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.Am J Hematol. 1993; 42: 81-85
- Hepatic iron Quantification on 3 Tesla (3 T) magnetic resonance (MR): Technical challenges and Solutions.Radiol Res Pract. 2013; 2013: 628150
- Hepatic iron concentration and total body iron stores in thalassemia major.N Engl J Med. 2000; 343: 327-331
- MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients.Blood. 2005; 106: 1460-1465
- Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.Blood. 2005; 105: 855-861
- Bone-marrow transplantation in a patient with sickle-cell anemia.N Engl J Med. 1984; 311: 780-783
- Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.Blood. 2017; 129: 1548-1556
- Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now?.Curr Opin Hematol. 2019; 26: 448-452
- Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion.Blood. 2020; 135: 2071-2084
- Neurologic complications after allogeneic marrow transplantation for sickle cell anemia.Blood. 1995; 85: 879-884
- Transfusion support for hematopoietic stem cell transplant recipients.in: Fung M.K. Anne E. Spitalnik S.L. Technical manual. 19th edition. AABB, Bethesda, MD2017: 683-694
- Complex transfusion issues in pediatric hematopoietic stem cell transplantation.Transfus Med Rev. 2016; 30: 202-208
- Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.Br J Haematol. 2005; 128: 668-675
Hendrickson J, Fasano R. Transfusion support of the patient with sickle cell disease undergoing transplantation. In:2018:111-136.
- Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor.Transfusion. 2009; 49: 1977-1986
- The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: a prospective, single-center, observational study.EClinicalMedicine. 2020; 24: 100432
- Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study.Lancet Haematol. 2017; 4: E553-E561
- Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLA-matched haematopoietic cell transplant for sickle cell disease.Br J Haematol. 2020; 189: 162-170
- The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation.Transfusion. 2014; 54: 1071-1080
- Blood transfusions and pulmonary complications after hematopoietic cell transplantation.Transfusion. 2016; 56: 653-661
- HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.N Engl J Med. 2014; 371: 339-348
- HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.Blood. 2012; 120: 4285-4291
- Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease.Biol Blood Marrow Transplant. 2013; 19: 820-830
- Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).Biol Blood Marrow Transplant. 2012; 18: 1265-1272
- Umbilical cord blood transplantation for children with thalassemia and sickle cell disease.Biol Blood Marrow Transplant. 2011; 17: 1375-1382
- Genetic therapies for sickle cell disease.Semin Hematol. 2018; 55: 76-86
- Red cell transfusion in paediatric patients with thalassaemia and sickle cell disease: current status, challenges and perspectives.Transfus Apher Sci. 2018; 57: 347-357
- Gene therapy in a patient with sickle cell disease.N Engl J Med. 2017; 376: 848-855
- Fatal sickle cell crisis after granulocyte colony-stimulating factor administration.Blood. 2001; 97: 3313-3314
- Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?.Cytotherapy. 2009; 11: 464-471
- Granulocytosis causing sickle-cell crisis.Lancet. 1998; 351: 959
- Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients.Blood Adv. 2018; 2: 2505-2512
- Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.Haematologica. 2018; 103: 778-786
- Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results.Haematologica. 2018; 103: 770-777
- Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.Haematologica. 2020; https://doi.org/10.3324/haematol.2019.236182
- Mobilization and collection of cells in the hematologic compartment for cellular therapies: stem cell collection with G-CSF/plerixafor, collecting lymphocytes/monocytes.Semin Hematol. 2019; 56: 248-256
- Hematopoietic stem and progenitor cells (HSPCs).in: Ratajczak M.Z. Stem cells: therapeutic applications. Springer International Publishing, Cham (Switzerland)2019: 49-77
- The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment.Blood. 2007; 110: 860-869
- Rapid mobilization reveals a highly engraftable hematopoietic stem cell.Cell. 2018; 172: 191-204.e10
- Collection of blood stem cells from patients with sickle cell anemia.Blood Cells Mol Dis. 2005; 35: 384-388
- Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.Mol Ther. 2012; 20: 230-238
- Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with β-thalassemia major.Transfusion. 2017; 57: 1031-1039
Article info
Publication history
Published online: December 22, 2020
Footnotes
Funding: The authors acknowledge support from the American Lebanese Syrian Associated Charities (Y. Zheng), National Blood Foundation Early-Stage Investigator’s Award (Y. Zheng), and the National Institutes of Health/National Heart Lung Blood Institute HL134696 and HL147879-01 (S.T. Chou).
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
